Inhibitor Therapeutics
Tampa, Florida, United States · Biotechnology, Healthcare, Health Care
Currently the first line treatment for BCCs on exposed areas such as the face and neck is Mohs Surgery which becomes increasingly challenging and leads to permanent scarring and disfiguration. As patients age as they may undergo hundreds of surgeries. Inhibitor believes that itraconazole has clinically meaningful effects on the BCCs, which led us to recruit a team of five experienced Mohs surgeons
Key facts
- Headquarters
- Tampa, Florida, United States
- Employees
- 3
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (INTI)
- Website
- inhibitortx.com
- Company page
Recent activity at Inhibitor Therapeutics
- : Inhibitor Therapeutics Enters Performance-Based Master Services Agreement with Frameshift Management (date Fundz recorded it)
- : SEC 8-K (5.02): On September 15, 2026, Inhibitor Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders where stockholders voted to elect six directors: Francis E. O’Donnell, Samuel J. Sears, Niraj Vasisht, Michelle Yanez, Michael Jerman, and Ronald E. Osman. Each director is elected to serve a one-year term expiring at the 2027 Annual Meeting of Stockholders, or until their earlier death, resignation, or removal. This election reflects the company's governance structure and outlines the new composition of its Board of Directors for the upcoming year.
- : SEC 8-K (7.01):
- : SEC 8-K (8.01): On March 31, 2026, Inhibitor Therapeutics, Inc. provided a press release detailing updates on its Itraconazole program for Gorlin Syndrome. The press release, attached as Exhibit 99.1, outlines clinical developments, formulation advancements, and intellectual property insights related to the program. It emphasizes the company's strategic focus on transforming its pipeline into revenue, along with the challenges posed by a competitive market. The press release serves as a substantial update on the company's clinical efforts and future objectives.
- : SEC 8-K (1.01): On February 19, 2026, Inhibitor Therapeutics, Inc. entered into a Securities Purchase Agreement with an institutional investor to sell 12,000,000 shares of its common stock for $3,000,000, at $0.25 per share. Additionally, the Company will issue a Common Stock Purchase Warrant allowing the Investor to purchase up to 7,000,000 shares at an exercise price of $0.35 per share. The proceeds from the financing are intended for working capital and general corporate purposes. The Financing is expected to close shortly after the filing date of February 24, 2026. The agreement includes customary representations, warranties, and covenants.
- : SEC 8-K (5.02):
- : SEC 8-K (1.01): On October 21, 2025, Inhibitor Therapeutics, Inc. entered into a performance-based master services agreement with Frameshift Management, Inc. Under this agreement, Frameshift will provide consulting services focused on biostatistics, regulatory affairs, business development, and strategic consulting to support Inhibitor's programs targeting basal cell carcinomas in Gorlin’s syndrome. The agreement stipulates that the consultant will be compensated with unvested equity, which is contingent upon meeting certain performance requirements. This collaboration aims to enhance Inhibitor's utilization of its proprietary itraconazole formulation. The agreement is strategically significant as it aligns with the company's focus on innovative treatments for rare diseases.
- : HedgePath Pharmaceuticals, Inc.
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Inhibitor Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Apr 2016 | Seed | $600K |
Leadership
- R. MD, Director
- Stefan Cross, Director
- W. CPA, Director
- Samuel Jr., Director
- Frank MD, Executive Officer, Director
- Garrison CPA, Executive Officer
- Nicholas Virca, Executive Officer
Verified email and direct lines for Inhibitor Therapeutics’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Companies similar to Inhibitor Therapeutics
- Lipella Pharmaceuticals · Biotechnology, Healthcare, Health Care, Medical, Therapeutics
- Immuneering · Biotechnology, Healthcare, Health Care, Medical, Therapeutics
- Kinnate Biopharma · Biotechnology, Healthcare, Health Care, Medical, Therapeutics
- Elevation Oncology · Biotechnology, Healthcare, Health Care, Medical, Therapeutics
- Century Therapeutics, Inc. · Biotechnology, Healthcare, Health Care, Medical, Therapeutics
About Inhibitor Therapeutics: questions and answers
What does Inhibitor Therapeutics do?
Currently the first line treatment for BCCs on exposed areas such as the face and neck is Mohs Surgery which becomes increasingly challenging and leads to permanent scarring and disfiguration. As patients age as they may undergo hundreds of surgeries. Inhibitor believes that itraconazole has clinically meaningful effects on the BCCs, which led us to recruit a team of five experienced Mohs surgeons
Where is Inhibitor Therapeutics headquartered?
Inhibitor Therapeutics is headquartered in Tampa, Florida, United States.
How many employees does Inhibitor Therapeutics have?
Inhibitor Therapeutics has about 3 employees.
Has Inhibitor Therapeutics raised funding?
Yes. Fundz has recorded 1 funding event for Inhibitor Therapeutics. The most recent, Seed of $600K, was in Apr 2016.
What is the latest news on Inhibitor Therapeutics?
On Oct 27, 2025, Inhibitor Therapeutics Enters Performance-Based Master Services Agreement with Frameshift Management
Is Inhibitor Therapeutics a public company?
Yes. Inhibitor Therapeutics is publicly traded under the ticker INTI.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy